Open AccessA Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
Author(s) -
Liyu Zhang,
Meng Wang,
Zeen Zhu,
Chenguang Ding,
Shengquan Chen,
Haibin Wu,
Ying Yang,
Fengyu Che,
Qiao Li,
Hui Li
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s302450
Subject(s) - aptamer , systematic evolution of ligands by exponential enrichment , in vivo , targeted therapy , microbiology and biotechnology , neuroblastoma , binding selectivity , chemistry , cancer research , flow cytometry , biology , biochemistry , cancer , rna , cell culture , genetics , gene
GD2 is a mainstream biomarker for neuroblastoma (NB)-targeted therapy. Current anti-GD2 therapeutics exhibit several side effects since GD2 is also expressed at low levels on normal cells. Thus, current anti-GD2 therapeutics can be compromised by the coexistence of the target receptor on both cancer cells and normal cells.